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Abstract
Purpose: Tracking cells in vivo using imaging can provide non-invasive information to understand the pharmacology,
efficacy, and safety of novel cell therapies. Zirconium-89 (t1/2 = 78.4 h) has recently been used to synthesize [
89Zr]Zr(oxinate)4
for cell tracking using positron emission tomography (PET). This work presents an in vitro approach to estimate the detection
limit for in vivo PET imaging of Jurkat T cells directly labeled with [89Zr]Zr(oxinate)4 utilizing clinical PET/CT and PET/MRI.
Methods: Jurkat T cells were labeled with varying concentrations of [89Zr]Zr(oxinate)4 to generate different cell-specific
activities (0.43–31.91 kBq/106 cells). Different concentrations of labeled cell suspensions (104, 105, and 106 cells) were seeded
on 6-well plates and into a 3 × 3 cubic-well plate with 1 cm3 cubic wells as a gel matrix. Plates were imaged on clinical PET/
CT and PET/MRI scanners for 30min. The total activity in each well was determined by drawing volumes of interest over
each well on PET images. The total cell-associated activity was measured using a well counter and correlated with imaging
data. Simulations for non-specific signal were performed to model the effect of non-specific radioactivity on detection.
Results: Using this in vitro model, the lowest cell number that could be visualized on 6-well plate images was 6.8 × 104,
when the specific activity was 27.8 kBq/106 cells. For the 3 × 3 cubic-well, a plate of 3.3 × 104 cells could be detected on
images with a specific activity of 15.4 kBq/106 cells.
Conclusion: The results show the feasibility of detecting [89Zr]Zr(oxinate)4-labeled Jurkat T cells on clinical PET systems. The
results provide a best-case scenario, as in vivo detection using PET/CT or PET/MRI will be affected by cell number, specific
activity per cell, the density of cells within the target volume, and non-specific signal. This work has important implications
for cell labeling studies in patients, particularly when using radiosensitive cells (e.g., T cells), which require detection of low
cell numbers while minimizing radiation dose per cell.
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Introduction
Cell therapy is emerging as a living drug for the treat-
ment of a range of conditions such as genetic diseases,
cancer, and autoimmune disorders. It has the potential
to radically change medical management and is the sub-
ject of considerable ongoing preclinical and translational
development. Kymriah™ and Yeskarta™, two cell-based
gene therapies for the treatment of acute lymphoblastic
and diffuse large B cell lymphoma (DLBCL), are two
promising examples of cellular therapies. Despite their
promise, very few cell products have been approved for
clinical use to date [1].
In order to successfully implement cell therapies and
translate them into clinical practice, a better understand-
ing of their biodistribution and persistence after
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
* Correspondence: lmtl2@cam.ac.uk; fag1000@cam.ac.uk
1Department of Radiology, University of Cambridge, Cambridge, UK
Full list of author information is available at the end of the article
Lechermann et al. EJNMMI Research           (2020) 10:82 
https://doi.org/10.1186/s13550-020-00667-5
administration is required. The success of cellular ther-
apy depends on the precise dosing, timing, and the
spatial distribution of administered cells to the site of ac-
tion in the body. Non-invasive, in vivo real-time tracking
of cells via imaging can provide much-needed informa-
tion and help optimize cell therapies both for discovery
research and clinical development.
Therapeutic cells can be labeled both directly (i.e.,
in vitro) or indirectly (i.e., in vivo) and be imaged non-
invasively using a range of techniques including single-
photon emission computed tomography (SPECT),
positron emission tomography (PET), magnetic resonance
imaging (MRI), and optical imaging [2]. Direct labeling of
leukocytes using technetium-99m or indium-111 for
SPECT imaging has been a routine clinical procedure to
image infection and inflammation since the 1980s. 111In-
SPECT has also been used for therapeutic cell tracking in
cancer patients [3–6], while indirect labeling approaches
have been employed for in vivo cellular PET imaging. For
example, 9-[4-[18F]fluoro-3-(hydroxymethyl)butyl]guanine
([18F]FHBG) has been used to track genetically modified
therapeutic cells in human studies [7, 8]. Compared to
other imaging modalities, PET has the potential to provide
superior sensitivity for cell tracking [9, 10].
Zirconium-89 (t1/2 = 78.4 h) has emerged recently as a
promising PET radioisotope for direct cell labeling [11–
13]. With its long half-life and residualizing properties in
cells, zirconium-89 lends itself to longitudinal cell im-
aging applications which require extended in vivo circu-
lation times and detection over several days [14].
[89Zr]Zr(oxinate)4 is a lipophilic compound that can
enter the cell by passive transport across the cell mem-
brane, exploiting a similar mechanism to that used to
label autologous leukocytes with indium-111 for clinical
cell imaging [15, 16]. [89Zr]Zr(oxinate)4-PET holds
promise to improve upon the sensitivity limitations en-
countered with indium-111 SPECT [9, 17], and clinical
imaging trials of this approach are currently on-going.
A key issue for cell tracking with these imaging
methods is sensitivity, i.e., the need to achieve sufficient
radioactivity density of labeled cells in the target region
for detection. This is a particular problem for radiosensi-
tive cells, such as T cells, whose survival is compromised
by high-density radiolabeling. Estimating the radioactiv-
ity density of labeled cells required for detection will be
useful in determining the radiolabeling density that pro-
vides the best compromise between cell survival and
in vivo detection.
To date, very few studies have investigated the limits
of detecting cells using PET [18–20]. This work is the
first aimed to address the sensitivity issue for cell track-
ing of radiosensitive T cells directly labeled with very
low amounts of [89Zr]Zr(oxinate)4. An in vitro approach
was employed, with cell viability assessed alongside
detection on clinical PET systems as a function of cell
number and radioactivity exposure per cell. To our
knowledge, this is the first study to examine the detec-
tion limit of 89Zr-labelled cells on human PET systems.
Materials and methods
All chemicals, unless otherwise noted, were acquired
from Sigma-Aldrich and used without further purifica-
tion. Human serum was purchased frozen from Sigma-
Aldrich. All water used was ultrapure (> 18.2 MΩcm−1).
Zirconium-89 was supplied as Zr4+ in a 1-M oxalic acid
(PerkinElmer) and was produced at the BV cyclotron
Amsterdam via the 89Y(p,n)89Zr reaction. Activity mea-
surements were made using a CRC-55t dose calibrator
(Capintec Inc. Florham Park, NJ) with a calibration fac-
tor of 493 for Zirconium-89.
Cell culture
Jurkat cells, a human lymphoblast cell line (ATCC, TIB-
152TM, LGC), were cultured in Roswell Park Memorial
Institute medium (RPMI, Gibco), supplemented with
10% (v/v) fetal bovine serum (Thermo Fisher), 200 U/l
penicillin, 0.1 g/l streptomycin, 10 mM HEPES, and 2
mM L-glutamate. Jurkat cells were maintained in sus-
pension in a standard CO2 incubator (5% CO2 v/v).
[89Zr]Zr(oxinate)4 synthesis
The [89Zr]Zr(oxinate)4 complex was synthesized in an
aqueous solution according to a published literature pro-
cedure [21] (Supporting Information Section 1). The
radiochemical purity and yield of [89Zr]Zr(oxinate)4 was
monitored using silica gel impregnated instant thin-layer
chromatography paper (ITLC-SG; Agilent Technologies)
in ethyl acetate (Supporting Fig. S1 and S2).
[89Zr]Zr(oxinate)4 labeling of Jurkat T cells and
determination of viability
3–5 × 106 Jurkat cells were washed with phosphate-
buffered saline (PBS) and re-suspended in 1.5 mL PBS or
complete RPMI medium at room temperature. One
hundred fifty-four to 430 kBq of [89Zr]Zr(oxinate)4 solu-
tion was incubated with the respective cell solutions for
30 min at room temperature in a scintillation vial. After
incubation, cells were centrifuged and washed twice with
PBS. The pellet and corresponding supernatants were
measured in a Triathler well counter (HIDEX, Turku,
Finland) to calculate the uptake efficacy [%]. Cells were
suspended in complete RPMI medium subsequently for
further experiments. Cell viability was determined by
trypan blue exclusion. Unlabeled Jurkat cells were used
as a control to examine changes in cell viability before
and after each 6-well plate scan or post-labeling for the
3 × 3 cubic-well plate. An overview of the detailed ex-
periment setup is shown in Fig. 1.
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Detection limit experiment
To explore the detection limit of 89Zr-labeled cells on
a human PET scanner, 89Zr-labeled Jurkat cells were
seeded in RPMI medium into 6-well plates at differ-
ent specific activities, ranging from 104 to 106 cells
per well. Additionally, varying concentrations of 89Zr-
labeled cells suspended in Geltrex™ matrix were
placed into a 3 × 3-well plate containing 1 cm3 cubic
wells in order to examine the effect of cell density on
detection. The 6-well plates and 3 × 3 cubic-well
plate were imaged on clinical PET/CT (GE Discovery
690) and PET/MR (GE SIGNA) systems (GE Health-
care, Waukesha, USA). The total radioactivity (kBq)
in each of the cell suspensions was determined by
well counter measurements. The specific activity (SA),
defined here as the radioactivity per 106 cells (kBq/
106 cells), was calculated for each well based on the
corresponding well counter measurement divided by
the total number of cells as counted in a
hemocytometer. For the 1-cm3 cubic wells, cell dens-
ity (106 cells/mL) was defined as the number of cells
contained in the 1-mL well volume. A detailed ac-
count of the experimental procedure is provided in
the Supporting Information Section 4.
89Zr-labeled cell PET imaging
PET/CT scanning of the well plates was performed for
30 min directly followed by a 30-min acquisition on
PET/MRI. Detailed acquisition parameters are provided
in Supporting Information (Sections 5 and 6; Fig. S4).
a
b
Fig. 1 Schematic overview of the setup for the a 6-well plate experiments and b 3 x 3 cubic-well plate experiment
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PET image analysis
For each experiment, the PET image from the PET/MRI
scan was rigidly registered to its PET/CT counterpart, and
both were resampled to the space of the CT image (1 × 1
× 1mm3 voxels). For each 6-well plate, utilizing the CT as
guidance, cylindrical volumes of interest (VOIs) were de-
fined for each well containing 89Zr-labeled cells by manu-
ally placing circular regions of 3.4-cm diameter on all
contiguous coronal slices encompassing the activity distri-
bution on PET images. Corresponding background VOIs
were generated by placing similarly sized cylindrical VOIs
within the three empty wells in each 6-well plate. In a
similar manner, cubic VOIs (1 cm3) were defined for each
well of the 3 × 3 cubic-well plate, with three identically
sized background VOIs defined in the area between the 3
× 3 cubic-well plate and the outer plastic case (Supporting
Fig. S4). The total activity (kBq) in each well was calcu-
lated by summing the radioactivity concentration (kBq/
mL) within the defined VOI and multiplying by the VOI
volume (mL).
As a measure of detectability, the contrast-to-noise ra-
tio (CNR) for wells containing 89Zr-labeled cells was cal-
culated according to Eq. 1:
CNRwell ¼
μwell − μbackground
σbackground
ð1Þ
where μwell and μbackground refer to the mean radioactivity
concentrations in each 89Zr-containing well VOI and for
the background VOIs respectively, and σbackground is the
standard deviation of voxel values in the background
VOIs. Image analysis was performed in Analyze 12.0
(AnalyzeDirect Inc., Overland Park, USA).
Calculation of the lower limit of detection (LLD), de-
fined as the minimum number of cells required for de-
tection on imaging, was performed by regressing specific
activity vs. CNR for all wells across all experiments to
obtain the 95% upper confidence interval (CI) limit on
CNR. The upper 95% CI value for CNR was subse-
quently substituted into the linear regression equation of
CNR vs. cell number per well to calculate LLD.
The detection probability of 89Zr-labeled cell suspen-
sions on PET/CT and PET/MRI as a function of cell
number was estimated through binomial logistic regres-
sion using Eq. 2:
Detection probability ¼ 1
1þ e − β0þβ1xð Þ
ð2Þ
where β0 and β1 refer to the logistic regression coeffi-
cients and x denotes the cell number [18].
Prior to logistic regression, binary classification of
PET/CT and PET/MR image CNR was performed using
the Rose criterion (i.e., classification using a threshold of
CNR = 5). To investigate the effect of surrounding
background radioactivity on the detection probability of
89Zr-labeled cells, eight different background levels cor-
responding to 10–80% of the radioactivity concentra-
tions in each 89Zr-containing well were simulated, with
σbackground estimated assuming a Poisson noise model.
Simulations were performed in Matlab 2016b (Math-
works Inc., Natick, NA, USA) and resulted in 248 syn-
thetic datasets.
For each 1 cm3 well of the 3 × 3 cubic-well plate, a re-
covery coefficient (RC) was calculated according to Eq. 3:
Recovery coefficient ¼ Measured activityð Þwell − Measured activityð Þbackground
Known activityð Þwell − Known activityð Þbackground
ð3Þ
where Measured activity corresponds to the total activity
in the well or background VOIs as measured on the PET
images and Known activity refers to the total activity of
the cell suspensions as measured in the well counter
with (Known activity)background = 0 kBq.
To investigate the effect of cell density and specific ac-
tivity on the recovery coefficient, the following model
was fitted to the 3 × 3 cubic-well plate data:
RCij ¼ ai log CDij∙SAij
 þ γ0
 
ij þ ϵij ð4Þ
where CD and SA refer to the cell density and specific
activity of well j = 1,...,9 when using scanner i = 1 (PET/
CT) or i = 2 (PET/MRI); αi and γ0 are the slope and
intercept respectively; and εij are within-group (i.e., scan-
ner) errors. Fitting was performed using a non-linear
mixed effects model implemented in Matlab 2016b, with
fixed effects for the product of cell density and specific
activity, and random effects accounting for differences in
RC between the two scanners.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
8.0; (GraphPad Software Inc., La Jolla, USA). Results are
presented as mean ± standard deviation (SD) or median
[range] as appropriate. The Anderson-Darling test was
used to assess distribution normality. Means between
the two groups were compared using Student’s two-
tailed t test, whereas the Kruskal-Wallis H test was used
for comparison when more than two groups were com-
pared. Correlations between continuous variables were
assessed using the Pearson correlation coefficient (r).
Bland-Altman analysis was used to evaluate differences
in well activity and CNR values between PET/CT and
PET/MRI. p values < 0.05 were considered statistically
significant.
Results
Eleven cell labeling experiments were performed with
different Zirconium-89 batches for [89Zr]Zr(oxinate)4
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tracer synthesis, using Jurkat cells with the same passage
number for each experiment. Overall, 11 and 12 6-well
plates with 33 and 36 wells containing 89Zr-labeled cells
were scanned within 6 independent experiments using
PET/CT and PET/MRI, respectively. Results from five
wells were excluded for both PET/CT and PET/MRI
owing to pipetting errors (three wells) and inability to
quantify the cell number (two wells). The 3 × 3 cubic-
well plate containing 89Zr-labeled cells in Geltrex™
matrix was scanned once each on PET/CT and PET/
MRI.
[89Zr]Zr(oxinate)4 synthesis and labeling of Jurkat T cells
The [89Zr]Zr(oxinate)4 complex was synthesized in an
aqueous solution at a mean radiochemical yield of 93.5%
± 3.1 (SD, n = 8) as indicated by thin-layer chromatog-
raphy and was used for cell labeling without further
purification. The labeling efficiency measured after a 30-
min incubation period ranged from 5.1 to 33.3% of the
added activity. Labeling and imaging did not significantly
affect the cell viability throughout the experiment (Sup-
porting Fig. S5).
Imaging and detection limit of 89Zr-labeled cells
For the 6-well plates, the total activity per well ranged
from 0.02 to 15.57 kBq and 0.01 to 24.47 kBq as mea-
sured by the gamma counter and on PET imaging, re-
spectively (Fig. 2a, b). The median cell number in the
106, 105, and 104 wells was 1.08 × 106, 1.45 × 105, and
8.50 × 104 respectively (Fig. 2c) with specific activities
ranging between 0.4 and 31.91 kBq/106 cells (Fig. 2d).
No statistically significant difference was observed be-
tween the median specific activities in different wells (p
= 0.71). For the 3 × 3 cubic-well plate, the total activity
per 1 cm3 well ranged from 0.01 to 12.22 kBq on PET
imaging and 0.00 to 9.95 kBq as measured by the gamma
counter. Specific activities ranged between 0.14 and
30.63 kBq/106 cells. Detailed information can be found
in Supporting Tables S2 and S3.
The total activity in each well as determined from
PET/CT and PET/MRI images showed a strong correl-
ation with the total cell-associated activity as measured
by the well counter (6-well plates: PET/CT: r = 0.84, p <
0.0001; PET/MRI: r = 0.85, p < 0.0001; 3 × 3 cubic-well
plate: PET/CT: r = 0.995, p < 0.0001; PET/MRI: r =
0.999, p < 0.0001, Fig. 3a, b). Well CNRs ranged from 0
Fig. 2 Individual value plots and median of a total activity [kBq] in 106, 105, and 104 wells as measured by the well counter; b total activity [kBq] in 106,
105, and 104 wells as obtained from PET images acquired using PET/CT and PET/MRI; c cell number in 106, 105, and 104 wells; and d specific activity
[kBq/106 cells] in different wells
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to 2106 for the 6-well plates and 0 to 4341 for the 3 × 3
cubic-well plate. A significant positive correlation was
observed between CNR and the total cell-associated ac-
tivity (6-well plates: PET/CT: r = 0.82, p < 0.0001; PET/
MRI: r = 0.83, p < 0.0001; Fig. 3c, d; 3 × 3 cubic-well
plate: PET/CT: r = 0.994, p < 0.0001; PET/MRI: r =
0.999, p < 0.0001, Fig. 3e). Similarly, well CNRs corre-
lated positively with specific activity (6-well plates: PET/
CT: r = 0.44, p = 0.02; PET/MRI: r = 0.49; p = 0.006,
Supporting Fig. S6a; 3 × 3 cubic-well plate: PET/CT: r =
0.85, p = 0.004; PET/MRI: r = 0.82; p = 0.007, Support-
ing Fig. S6b). Furthermore, a significant positive correl-
ation between the CNR and cell number for each well
could be observed within each specific activity group for
both scanners (Fig. 3f). For PET/CT, correlation coeffi-
cients for each specific category group were as follows:
0–5 kBq/106 cells: r = 0.81 (p = 0.003); 5–15 kBq/106
cells: r = 0.80 (p = 0.001); 15–35 kBq/106 cells: r = 0.98
(p = 0.02), whereas for PET/MRI, these were as follows:
0–5 kBq/106 cells: r = 0.79, p = 0.0008; 5–15 kBq/106
Fig. 3 Pearson correlation between the total cell-associated activity [kBq] measured in the well counter and on PET images for a 6-well plates
and b 3 × 3 cubic-well plate. c Pearson correlation of PET/CT and PET/MRI CNR vs. total cellular activity [kBq] for 6-well plates. d Individual value
plot and median of CNR per specific activity category for both PET/CT and PET/MRI for 6-well plates. e Pearson correlation of PET/CT and PET/MRI
CNR vs. total cellular activity [kBq] for 3 × 3 cubic-well plate. f Scatter plot of PET/CT and PET/MRI well CNR vs. cell number per specific activity
category. CNR: contrast-to-noise ratio
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cells: r = 0.83, p = 0.0005; 15–35 kBq/106 cells: r = 0.98,
p = 0.02.
PET/CT and PET/MRI results strongly correlated for
both total well activity and CNRs (Supporting Fig. S8a
and S8c). Bland-Altman analysis indicated good agree-
ment between PET/CT and PET/MRI indices of total
well activity and CNRs (Supporting Fig. S8b and S8d).
Figure 4 illustrates representative coronal PET images
of 6-well plates with different numbers of 89Zr-labeled
cells and specific activities per well. In general, lower cell
numbers with a higher specific activity could be detected
with a higher contrast-to-noise ratio compared to wells
with a higher cell number and a lower specific activity.
In the example images shown, 5.2 × 105 cells with a spe-
cific activity of 2.2 kBq/106 cells could be clearly visual-
ized (Fig. 4, A2), whereas the lowest cell number that
could be detected was 6.8 × 104, when the specific activ-
ity was 27.8 kBq/106 cells (Fig. 4, B2). Similarly, 1.1 ×
106 cells with a specific activity of 0.7 kBq/106 cells could
not be clearly visualized on PET images of the 3 × 3
cubic well structure (Fig. 5, L1) while 3.3 × 104 cells
could be detected when the specific activity was 15.4
kBq/106 cells (Fig. 5, M2).
The theoretical lower limit of detection (LLD) for
PET/CT and PET/MRI, together with the specific activ-
ity at this LLD, is given in Table 1. Detailed calculations
for obtaining LLD are presented in Supporting Fig. S9.
The calculations yielded a slightly lower LLD for PET/
MRI compared to PET/CT where values were of the
order of 105 cells. The LLD values obtained for the 3 × 3
cubic-well plate were lower than those obtained for the
6-well experiment, which can be explained by the higher
density in the 1-cm3 wells (Supporting Table S4).
For the 6-well plates, plots of detection probability vs.
cell number for both scanners are presented in Fig. 6. At
the LLD, 89Zr-labeled cells could be detected with > 90%
probability. As expected, a decrease in the detection
probability of 89Zr-labeled cell suspensions was observed
for increasing background levels and decreasing cell
numbers per well. For a given detection probability and
depending on the level of background activity, differ-
ences of two orders of magnitude could be observed in
the minimum number of detectable 89Zr-labeled cells
(Supporting Table S5).
Figure 7 presents the image recovery coefficient as a
function of cell density and specific activity for the 3 × 3
cubic-well plate. In general, an improvement in contrast
recovery was observed with increasing specific activity
and cell density, indicating that the distribution of cells
within a defined volume is an additional factor affecting
detection. For the 3 × 3 cubic-well plate, convergence to
a recovery coefficient of 1 for the specific activity ob-
tained at LLD (~ 5.3 kBq/106 cells for both scanners)
would require ~ 8.8 × 106 cells/mL.
Discussion
Cell labeling and tracking is a rapidly growing area of
clinical interest, particularly in the context of monitoring
and evaluating novel cellular therapies (such as CAR-T
cells). The sensitivity and quantification of cell labeling
approaches are important for the successful clinical
translation of this technology, but little research has
been undertaken to evaluate this on a clinical scanner.
[89Zr]Zr(oxinate)4 has been used as a direct cell labeling
method for cellular tracking in preclinical models and
holds great promise for clinical imaging due to the su-
perior sensitivity offered by PET imaging compared to
the conventional SPECT approach using [111In]In-oxine.
This is the first study to examine the theoretical detec-
tion limit and quantification of 89Zr-labeled cells on a
human PET system with respect to therapeutic cell
tracking. Using an in vitro approach, cell numbers in the
magnitude of 105 and 104 with activity concentrations as
low as 250 Bq/mL and 565 Bq/mL respectively could be
detected during a 30-min scan. These activity concentra-
tions are higher than those reported for [18F]-FDG la-
beled cells imaged in vitro on a clinical PET/CT, where
activity concentrations as low as 50 Bq/mL could be vi-
sualized during a 5 min acquisition. This difference can
in part be attributed to the much higher positron decay
probability of fluorine-18 (96.9%) compared to
zirconium-89 (22.7%), with another factor being the
emission of coincident non-annihilation photons for
zirconium-89, which leads to photon events that reduce
image contrast. However, a major advantage of
zirconium-89 over fluorine-18 is its much longer half-
life (t1/2 = 78.4 h vs. 109min), which is a requirement for
longitudinal cell tracking over several days. Furthermore,
zirconium-89 is a residualizing isotope, with intracellular
binding to nuclear and cytoplasmic proteins ensuring re-
tention inside the cell.
During a typical clinical white blood scintigraphy pro-
cedure, 10.0–18.5MBq of 111In-labeled leucocytes are
injected into patients to track cells and image sites of in-
flammation and infection [22]. Tumor-infiltrating lym-
phocytes and peripheral blood mononuclear cells could
be tracked and imaged in patients with a maximum of
1.3–3.7 kBq/106 cells with the corresponding range of
injected number of cells being 1.5–9.2 × 109 [3, 6]. This
specific activity corresponds to the lowest specific activ-
ity of 89Zr-labeled cells in this study, where cells in the
magnitude of 105 could still be detected. With its super-
ior sensitivity over SPECT, PET has the potential to de-
tect cells labeled with less activity or alternatively a
smaller number of cells. Preclinically, 89Zr-labeled cells
have been tracked with PET at approximately 10 times
lower activities compared to those labeled with Indium-
111 [23]. Recent developments in the whole-body PET
scanner technology offer the potential of sensitivity to
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increase by a further 40-fold for the whole body and 4–
5-fold for a single organ [24]. Compared to conventional
PET, this could allow the use of lower cellular activities
or even fewer cells could be detected within the organ of
interest.
Given the radiosensitivity of lymphocytes and their subsets,
we examined the lower end of the radioactivity spectrum as-
sociated with cells for imaging purposes that have been
shown not to cause significant cell damage. In preclinical ani-
mal models, the damage to γδ-T cells was minimal at specific
activities up to 20 kBq/106 cells [13], whereas CAR-T cells
maintained their functionality and viability up to 70 kBq/106
cells [21] and 89Zr-labeled bone marrow cells were not al-
tered at 16.6 kBq/106 cells and could be imaged up to 7 days
after injection in vivo [11]. Therefore, our focus in this study
was to quantify the lower limits of cell detection with specific
Fig. 4 PET images of 6-well plates containing 89Zr-labeled Jurkat cells acquired using PET/CT and PET/MRI together with their corresponding co-
registered CT image. Cell numbers and specific activities per well (kBq/106 cells; indicated parenthetically) were as follows: (A1) 1.36 × 106 cells
(2.70). (A2) 5.20 × 105 cells (2.18). (A3) 1.45 × 105 cells (1.57). (B1) 3.83 × 105 cells (31.91). (B2) 6.75 × 104 cells (27.77). (B3) 1.00 × 104 cells (18.37).
(C1) 8.45 × 105 cells (7.83). (C2) 1.65 × 105 cells (3.57). (C3) 6.10 × 104 cells (6.93)
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activities of up to ~ 35 kBq/106 cells. Our data suggests that
cells with specific activities as low as 0.7–2.2 kBq/106 cells
can still be visualized on a human PET scanner which is
promising for the potential use of 89Zr-labeled cells in vivo.
The specific activity per cell is one of the major limit-
ing factors for cellular imaging using radioactive labeling
approaches, given that labeling and tracking must not
significantly alter the phenotype, viability, and function-
ality of labeled cells. Ideally, the radioactivity per cell
should not affect any of these characteristics but at the
same time should be sufficient to allow the visualization
of labeled cells on imaging. These characteristics are piv-
otal prerequisites that need to be incorporated into all
in vivo cell tracking and especially clinical imaging
scenarios.
We have shown that detectability, as measured by the
contrast-to-noise ratio, is dependent on the total cellular
activity, which is the product of cell number and the spe-
cific activity (activity/106 cells). Figure 4 demonstrates the
strong interplay between the cell number and specific ac-
tivity for cell detection in wells. While 6.1 × 104 cells with
a specific activity of 6.9 kBq/106 cells (C3) were not visible
on imaging, a similar number of cells (6.8 × 104) could be
detected with a 4-times higher specific activity (B2). Like-
wise, 1.7 × 105 cells could not be detected (C2) compared
to 5.2 × 105 cells (A2) with a similar specific activity.
Fig. 5 PET images of 3 × 3 cubic-well plate containing 89Zr-labeled Jurkat cells suspended in Geltrex™ matrix in a 1-cm3 cube acquired using
PET/CT and PET/MRI together with their a corresponding co-registered CT image and b in greyscale. Cell numbers and specific activities per well
(kBq/106 cells; indicated in parenthesis) were as follows: L1: 1.07 × 106 (0.67). L2: 1.50 × 105 (0.42). L3: 6.70 × 104 (0.14). M1: 8.20 × 105 (7.23). M2:
3.25 × 104 (15.41). M3: 3.61 × 104 (6.61). H1: 3.99 × 105 (30.63). H2: 1.21 × 105 (8.47). H3: 6.20 × 104 (6.60)
Table 1 Theoretical lower limit of detection (LLD) for PET/CT and PET/MRI with respect to cell number and specific activity
6-well plates 3 × 3 cubic-well
LLDPET/MRI LLDPET/CT LLDPET/MRI LLDPET/CT
Cell number 5.24 × 105 (1.05 × 104)* 5.88 × 105 (1.07 × 104)* 4.56 × 105 (2.84 × 103)* 4.83 × 105 (3.22 × 103)*
Specific activity [kBq/106 cells] 3.26 (0.07)* 3.72 (0.07)* 5.46 (0.03)* 5.25 (0.04)*
*Values in parentheses indicate the theoretical LLD values according to the Rose criterion (CNR = 5) as a threshold for detectability
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Similarly, Fig. 5 shows that 3.3 × 104 cells with a specific
activity of 15.4 kBq/106 cells could just be visualized (M2)
while 3.6 × 104 cells carrying less than half the specific ac-
tivity could not be detected (M3).
The limitations of this work include that the imaged
cell suspensions in each well are not a true
representation of an in vivo cellular infiltration. Images
revealed that cells tended to coalesce into “hot spots”
within the wells. Dispersal circulation and infiltration
in vivo may result in less dense accumulation, a feature
which will reduce detectability. As illustrated in Fig. 7,
the ability to visualize 89Zr-labelled cell deposits will not
Fig. 6 Detection probability of 89Zr-labeled cell suspensions at different background levels for a PET/CT and b PET/MRI. μw, μb: mean radioactivity
concentration in 89Zr-containing wells and the background respectively
Fig. 7 Recovery coefficient as a function of cell density (106 cells/mL) and specific activity (kBq/106 cells) for the 3 × 3 cubic-well plate. a Scatter plot of
recovery coefficient vs. cell density and specific activity values and corresponding fit surface obtained through a logarithmic model function: y = 0.11 ×
log(CD × SA) + 0.57; CD = cell density; SA = specific activity. b Contour plot of specific activity as a function of recovery coefficient and cell density.
The contours correspond to specific activities ranging from 10 to 50 kBq/106cells. c Contour plot of recovery coefficient as a function of specific activity
and cell density. Contour lines indicate recovery coefficients ranging from 0.1 to 1.0
Lechermann et al. EJNMMI Research           (2020) 10:82 Page 10 of 12
only be influenced by the specific activity on cells and
cell number, but also the distribution and density of cells
within the target region. The effect of cell density on de-
tectability can be observed in Fig. 5, where wells with
similar specific activities (7.2 kBq/106, M1 vs. 6.6 kBq/
106, M3) could and could not be visualized respectively,
owing to differences in cell density (8.2 × 105 cells/mL,
M1 vs. 3.6 × 104 cells//mL, M3).
Similarly, we have not accounted for dilution of the
radioactive signal over time due to cell proliferation as
the plates were only imaged once directly after labeling.
Signal dilution could significantly affect in vivo detection
at later time points. Imaging 7 days after injection of
89Zr-labeled cells results in an approximately 25% de-
crease of total cellular activity due to radioactive decay
alone, without accounting for additional effects of label
dilution due to cellular proliferation.
Our measured data also did not account for non-
specific radioactivity, which will decrease the contrast-
to-noise ratio and therefore the detectability. As a
consequence, our measured data shows unusually
high CNRs that would normally not be observed on
patient images. Cells labeled with [89Zr]Zr-(oxinate)4
cannot be distinguished from dead cells, and the leak-
age of activity from dead cells is likely to account for
non-specific activity in neighboring tissues and bone
over time due to the bone-seeking properties of
Zirconium-89. The detection limit of 89Zr-labeled
cells is expected to be higher for in vivo cell tracking,
because of non-specific signal, higher photon attenu-
ation, and a higher level of scatter and random coin-
cidences potentially reducing contrast and increasing
image noise. In an attempt to model the effect of
non-specific radioactivity on detection, simulations for
a non-specific background signal were performed. As
expected, a decrease in detection probability was ob-
served with increasing background levels. The number
of cells required to achieve a detection probability of
90% increased by approximately two orders of magni-
tude for backgrounds ranging from 10 to 80% of the
radioactivity concentration in wells. Taken together,
the results provide a best-case scenario for the
in vivo detection of 89Zr-labeled cells on clinical PET
systems.
Conclusion
[89Zr]Zr(Oxinate)4 offers a promising solution to the
emerging need for a long-lived PET labeling approach
for in vivo cell tracking. This study shows the feasi-
bility of detecting 89Zr-labeled cells on human PET/
CT and PET/MRI scanners and presents detection
limit data that could be used to guide in vivo cell
tracking studies using [89Zr]Zr(oxinate)4 in the future.
This work has important implications for human cell
labeling procedures, which require the detection of
low cell numbers while minimizing radiation dose per
cell, particularly when using radiosensitive cells such
as T lymphocytes or CAR T cells.
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